PWPCM
PACB icon

Perella Weinberg Partners Capital Management’s Pacific Biosciences PACB Stock Holding History

Perella Weinberg Partners Capital Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-286,996
Closed -$1.74M – 127
2019
Q2 		$1.74M Hold
286,996
– – 0.08% 156
2019
Q1 		$2.08M Sell
286,996
-16,827
-6% -$122K 0.1% 138
2018
Q4 		$2.25M Buy
+303,823
New +$1.93M 0.14% 132

Other funds holding PACB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
KLCMU
Kite Lake Capital Management (UK) London, United Kingdom $125M AUM 198.01% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Perella Weinberg Partners Capital Management's PACB Position: Q3 2019 in Review

Perella Weinberg Partners Capital Management sold out of Pacific Biosciences (PACB) in Q3 2019, closing a stake of 286,996 shares — an estimated $1.74M sold.

Perella Weinberg Partners Capital Management first reported a position in PACB in Q4 2018 and held it in 3 quarters. The position peaked at $2.25M in Q4 2018. 148 funds tracked by Wall St. Rank hold PACB as of Q3 2019.

  • Perella Weinberg Partners Capital Management reported no remaining Pacific Biosciences position as of Q3 2019 after selling out during the quarter.
  • Perella Weinberg Partners Capital Management sold 286,996 Pacific Biosciences shares in Q3 2019, an estimated $1.74M.
  • Perella Weinberg Partners Capital Management first reported a position in Pacific Biosciences in Q4 2018 and held it in 3 quarters.
  • Perella Weinberg Partners Capital Management's Pacific Biosciences position peaked at $2.25M in Q4 2018.
  • 148 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2019.

Based on Perella Weinberg Partners Capital Management's 13F filing for Q3 2019, filed 8 Nov 2019.